Double-blind, placebo-controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 mRNA-Expressing platinum-resistant ovarian Cancer (PENELOPE)

Journal of Clinical Oncology

Volumn 34, Issue 21, 2016, Pages 2516-2525

  Kurzeder, Christian ^a   Bover, Isabel ^f   Marḿe, Frederik ^b   Rau, Joern ^c   Pautier, Patricia ^j   Colombo, Nicoletta ^l   Lorusso, Domenica ^m   Ottevanger, Petronella ⁿ   Bjurberg, Maria ^o   Marth, Christian ^p   Barretina Ginesta, Pilar ^g   Vergote, Ignace ^q   Floquet, Anne ^k   Campo, Josep M Del ^h   Mahner, Sven ^d   Bastíere Truchot, Lydie ^r   Martin, Nicolas ^r   Oestergaard, Mikkel Z ^r   Kiermaier, Astrid ^r   Schade Brittinger, Carmen ^c   Polleis, Sandra ^e   Bois, Andreas Du ^a   Gonzalez Martin, Antonio ⁱ   more..

^a KLINIKEN ESSEN MITTE   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e AGO Study Group   (Germany)

^f HOSPITAL SON LLÀTZER   (Spain)

^g CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^h HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁱ MD ANDERSON CANCER CENTER   (Spain)

^j INSTITUT GUSTAVE ROUSSY   (France)

^k INSTITUT BERGONIÉ   (France)

^l UNIVERSITY OF MILANO BICOCCA   (Italy)

^m NATIONAL CANCER INSTITUTE   (Italy)

ⁿ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^o LUND UNIVERSITY HOSPITAL   (Sweden)

^p INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^q UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^r F HOFFMANN LA ROCHE LTD   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 3; GAMMA GLUTAMYLTRANSFERASE; GEMCITABINE; MESSENGER RNA; PACLITAXEL; PERTUZUMAB; PLACEBO; PLATINUM DERIVATIVE; TOPOTECAN; CARBOPLATIN; ERBB3 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ACUTE HEART INFARCTION; ADD ON THERAPY; ADULT; AGED; ALOPECIA; ANTIANGIOGENIC THERAPY; ARTICLE; ASTHENIA; BRAIN ISCHEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL EVALUATION; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; ENCEPHALITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENE EXPRESSION; HAZARD RATIO; HUMAN; HYDROCEPHALUS; HYPERTENSION; HYPOKALEMIA; INTESTINE OBSTRUCTION; LEUKOPENIA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CARCINOMA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; SENSITIVITY ANALYSIS; SIDE EFFECT; SINGLE BLIND PROCEDURE; THROMBOCYTOPENIA; TRANSLATIONAL RESEARCH; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; CLINICAL TRIAL; DRUG RESISTANCE; GENETICS; MORTALITY; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DOUBLE-BLIND METHOD; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; RECEPTOR, ERBB-3; RNA, MESSENGER;

EID: 84978785964     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.66.0787     Document Type: Article

References (16)

1. Baselga J, Corte's J, KimSB, et al: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109-119, 2012
2. Swain SM, Baselga J, Kim SB, et al: Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372:724-734, 2015
3. Swain SM, Kim SB, Corte's J, et al: Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, doubleblind, placebo-controlled, phase 3 study. Lancet Oncol 14:461-471, 2013
4. Bezler M, Hengstler JG, Ullrich A: Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells. Mol Oncol 6:516-529, 2012
5. Makhija S, Amler LC, Glenn D, et al: Clinical activity of gemcitabine plus pertuzumab in platinumresistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol 28:1215-1223, 2010
6. Chakrabarty A, S'anchez V, Kuba MG, et al: Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc Natl Acad Sci USA 109:2718-2723, 2012
7. Nagumo Y, Faratian D, Mullen P, et al: Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: Implications for pertuzumab sensitivity. Mol Cancer Res 7:1563-1571, 2009
8. Kaye SB, Poole CJ, Danska-Bidzinska A, et al: A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer. Ann Oncol 24:145-152, 2013
9. Gonzalez-Martin A, Pautier P, Mahner S, et al: Pertuzumab plus chemotherapy for platinumresistant ovarian cancer: Safety run-in results of the PENELOPE trial. Int J Gynecol Cancer (in press)
10. Aghajanian C, Goff B, Nycum LR, et al: Independent radiologic review: Bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer. Gynecol Oncol 133:105-110, 2014
11. Burger RA, Brady MF, Rhee J, et al: Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer. Gynecol Oncol 131: 21-26, 2013
12. Husain A, Wang YV, Frederiksen R, et al: Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab (BV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol 32:15S, 2014 (suppl; abstr 5540)
13. Floquet A, Vergote I, Colombo N, et al: Progression-free survival by local investigator versus independent central review: Comparative analysis of the AGO-OVAR16 Trial. Gynecol Oncol 136:37-42, 2015
14. Pujade-Lauraine E, Hilpert F, Weber B, et al: Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol 32:1302-1308, 2014
15. Poveda AM, Selle F, Hilpert F, et al: Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: Analysis by chemotherapy cohort of the randomized phase III AURELIA trial. J Clin Oncol 33:3836-3838, 2015
16. Amler LC: HER3 mRNA as a predictive biomarker in anticancer therapy. Expert Opin Biol Ther 10:1343-1355, 2010